Other Events ·
NeuroSense signs deal to supply PrimeC for ALS via potential pathway targeting first revenues in H1 2027
NRSNNeuroSense Therapeutics Ltd.
NeuroSense Therapeutics signed a strategic collaboration with an advisor to advance the revenue-generating supply of its lead ALS candidate, PrimeC, through a licensed clinical treatment center in the U.S. The company targets generating first revenues from PrimeC supply in the first half of 2027, contingent on completing legal, regulatory, and operational requirements. Consideration for the advisor includes equity and a success-based percentage of net revenues from qualifying sales. This agreement aims to establish an initial revenue stream while the company continues clinical programs for ALS and Alzheimer's disease. NeuroSense Therapeutics is a biotechnology company developing therapeutic candidates for neurodegenerative diseases.